Denmark's national basic medicines list for general practitioners expanded to include anxiety, smoking cessation, migraine and type 2 diabetes, consolidating regional lists.
Medicinrådet (Danish Medicines Council) · DenmarkPå medicinraadet.dk kan brugerne få hjælp af chatbotten MAIA til at finde svar på faktuelle spørgsmål om habilitet, Medicinrådets vurderinger af nye lægemidler, faglige begreber og meget mere. Chatbotten bruger kunsti...
Medicinrådet (Danish Medicines Council) · DenmarkDanish Medicines Council publishes new brief guidance for psychiatrists and GPs on ADHD medication prescribing.
Medicinrådet (Danish Medicines Council) · DenmarkDanish Medicines Council announces collaboration with DARE on real-world data initiatives.
Medicinrådet (Danish Medicines Council) · DenmarkDanish Medicines Council decided to develop a new treatment guideline for hormone therapy in menopausal women and update six existing guidelines.
Medicinrådet (Danish Medicines Council) · DenmarkDanish health authorities launch coordinated effort to improve information for women and support healthcare professionals in menopause management and treatment.
Medicinrådet (Danish Medicines Council) · Denmark01. september 2026
Medicinrådet (Danish Medicines Council) · DenmarkPatientrepræsentanter deltager i næsten alle Medicinrådets fagudvalg, hvor de bidrager med viden om, hvordan sygdom og behandling påvirker patienters og pårørendes hverdag. Deres perspektiver er med til at kvalificere...
Medicinrådet (Danish Medicines Council) · DenmarkThe Danish Medicines Council and Amgros have extended the deadline for pharmaceutical companies to propose alternative pricing agreements.
Medicinrådet (Danish Medicines Council) · DenmarkThe Danish Medicines Council's recommendation on mavacamten reimbursement has not yet entered into force.
Medicinrådet (Danish Medicines Council) · DenmarkMedicinrådet recommends a new cardiac medicine for patients without alternative treatment options.
Medicinrådet (Danish Medicines Council) · DenmarkMedicinrådet recommends brexucabtagene autoleucel (Tecartus), an advanced therapy medicinal product, for blood and lymph cancer patients under a performance-based risk-sharing agreement.
Medicinrådet (Danish Medicines Council) · DenmarkDanish Medicines Council recommends CAR-T cell therapy brexucabtagene autoleucel for acute lymphoblastic leukaemia and mantle cell lymphoma under an outcome-based risk-sharing agreement.
Medicinrådet (Danish Medicines Council) · DenmarkDanish Medicines Council recommends against reimbursement of givinostat for Duchenne muscular dystrophy citing insufficient evidence on effect magnitude and duration.
Medicinrådet (Danish Medicines Council) · DenmarkDanish Medicines Council reaffirms recommendation for burosumab in children with X-linked hypophosphatemia following clinical experience review and price renegotiation.
Medicinrådet (Danish Medicines Council) · Denmark